Evidence map›Paper›PMID 36627822›Full record

ArticleCNS neuroscience & therapeutics2023

Alpinetin inhibits neuroinflammation and neuronal apoptosis via targeting the JAK2/STAT3 signaling pathway in spinal cord injury.

Shining Xiao, Yu Zhang, Zihao Liu, Anan Li, Weilai Tong, Xu Xiong, Jiangbo Nie, Nanshan Zhong, Guoqing Zhu, Jiaming Liu and 1 more

Open access · goldFull text read
In one paragraph

Article in CNS neuroscience & therapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 1 pooled it
12.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 1 synthesis or guideline pooled it, 103 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Shining XiaoDepartment of Orthopedics, The First Affiliated Hospital of Nanchang University, Nanchang, China.ORCID 0000-0001-7600-8525
Yu ZhangDepartment of Orthopedics, The First Affiliated Hospital of Nanchang University, Nanchang, China.ORCID 0000-0002-4387-0466
Zihao LiuDepartment of Orthopedics, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Anan LiDepartment of Orthopedics, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Weilai TongDepartment of Orthopedics, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Xu XiongDepartment of Orthopedics, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Jiangbo NieDepartment of Orthopedics, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Nanshan ZhongDepartment of Orthopedics, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Guoqing ZhuMedical Innovation Center, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Jiaming LiuDepartment of Orthopedics, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Zhili LiuDepartment of Orthopedics, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Nanchang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA growing body of research shows that drug monomers from traditional Chinese herbal medicines have antineuroinflammatory and neuroprotective effects that can significantly improve the recovery of motor function after spinal cord injury (SCI). Here, we explore the role and molecular mechanisms of Alpinetin on activating microglia-mediated neuroinflammation and neuronal apoptosis after SCI.

methodsStimulation of microglia with lipopolysaccharide (LPS) to simulate neuroinflammation models in vitro, the effect of Alpinetin on the release of pro-inflammatory mediators in LPS-induced microglia and its mechanism were detected. In addition, a co-culture system of microglia and neuronal cells was constructed to assess the effect of Alpinetin on activating microglia-mediated neuronal apoptosis. Finally, rat spinal cord injury models were used to study the effects on inflammation, neuronal apoptosis, axonal regeneration, and motor function recovery in Alpinetin.

resultsAlpinetin inhibits microglia-mediated neuroinflammation and activity of the JAK2/STAT3 pathway. Alpinetin can also reverse activated microglia-mediated reactive oxygen species (ROS) production and decrease of mitochondrial membrane potential (MMP) in PC12 neuronal cells. In addition, in vivo Alpinetin significantly inhibits the inflammatory response and neuronal apoptosis, improves axonal regeneration, and recovery of motor function.

conclusionAlpinetin can be used to treat neurodegenerative diseases and is a novel drug candidate for the treatment of microglia-mediated neuroinflammation.

Indexed as

FlavonesNeuroinflammatory DiseasesSpinal Cord InjuriesAnimalsApoptosisFlavanonesInflammationJanus Kinase 2LipopolysaccharidesMicrogliaRatsRats, Sprague-DawleySignal TransductionSpinal CordSTAT3 Transcription FactoralpinetinFlavanonesFlavonesJak2 protein, ratJanus Kinase 2LipopolysaccharidesStat3 protein, ratSTAT3 Transcription FactorAlpinetinJAK2/STAT3 pathwayneurinflammationneuronal apoptosisspinal cord injury

Identifiers

PMID36627822
PMCPMC10018110
OpenAlexW4315497994

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read60
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.